New trials, publications, preprints and grants on this target, month by month.
Trial
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes
11 Nov 2026· PHASE4 · NOT_YET_RECRUITING· CTGOV
Trial
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
1 Nov 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
Cicatricial Ectropion in the Setting of IL-13 Inhibition.
1 Oct 2026· Journal of drugs in dermatology : JDD· PUBMED
Publication
Evidence that IL-4/IL-13-Responsive IGFLs Promote Allergic Skin Inflammation.
30 Sept 2026· The Journal of investigative dermatology· PUBMED
Publication
IL-13 and skin fibrosis in inflammatory skin diseases.
24 Sept 2026· Frontiers in immunology· PUBMED
Publication
Case Report: Differential response to IL-13 inhibition: lebrikizumab following primary tralokinumab failure in atopic dermatitis.
23 Sept 2026· Frontiers in medicine· PUBMED
Publication
CCL5, CLEC11A, IL-7, IL-8, and IL-13: Diagnostic Serum Biomarkers of Gastric Cancer Identified in a 48-Multiplex Panel.
9 Sept 2026· Oncology· PUBMED
Publication
Mast cell-derived IL-13 as a driver of Crohn disease-associated intestinal fibrosis.
1 Sept 2026· Inflammatory bowel diseases· PUBMED
Publication
Persistent Patch Test Reactivity to Compositae Mix and Sesquiterpene Lactone Mix During Anti-IL-4/IL-13 Therapy in Two Cases.
28 Aug 2026· Contact dermatitis· PUBMED
Publication
Case Report: Effective IL-4/IL-13 axis suppression and resolution of severe atopic dermatitis by dupilumab monotherapy in a patient with IPEX syndrome.
17 Aug 2026· Frontiers in immunology· PUBMED
Publication
Nasal Lavage IL-4 and IL-13 in Cystic Fibrosis-Related Chronic Rhinosinusitis: Associations With Disease Severity and Potential Implications for Targeted Therapies.
13 Aug 2026· International forum of allergy & rhinology· PUBMED
Publication
Discovery and Development of a TGFβ3/IL-13 Plasma Risk Score for Preoperative Discrimination of Benign and Malignant Ovarian Adnexal Masses.
28 Jul 2026· Diagnostics (Basel, Switzerland)· PUBMED
Publication
Comment on 'Should Paradoxical Psoriasis Trigger Rheumatological Surveillance During IL-4/IL-13 Blockade?'.
24 Jul 2026· Clinical and experimental dermatology· PUBMED
Publication
IL-13 signaling in cDC2 is required for systemic anaphylactic responses.
9 Jul 2026· Proceedings of the National Academy of Sciences of the United States of America· PUBMED
Publication
Elevated IL-4 and IL-13 Expression in Hailey-Hailey Disease: Evidence for Th2-Mediated Pathogenesis and Targeted Treatment.
6 Jul 2026· Journal of cutaneous pathology· PUBMED
Publication
Indole-3-carbinol attenuates DNCB-induced atopic dermatitis in mice by reducing inflammation and IL-4/IL-13 expression.
2 Jul 2026· Biomolecules & biomedicine· PUBMED
Publication
Comment on: Bronchodilator response is linked with uncontrolled moderate-to-severe childhood asthma and elevated IL-4 and IL-13.
1 Jul 2026· Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology· PUBMED
Publication
IL-4/IL-13-Driven Dysregulation of Epidermal Lipid Metabolism in Atopic Dermatitis: An Immunometabolic Link Between Type 2 Inflammation and Barrier Dysfunction.
22 Jun 2026· Cells· PUBMED
Publication
CagA-dependent expression of anti-inflammatory cytokine IL-13 and TNFRSF member Fn14 in Helicobacter pylori infected gastric cells and tissues.
16 Jun 2026· Frontiers in microbiology· PUBMED
Publication
The airway epithelial muco-inflammatory response to IL-13 is exacerbated in cystic fibrosis.
1 Jun 2026· American journal of respiratory cell and molecular biology· PUBMED
Publication
Bronchodilator response is linked with uncontrolled moderate-to-severe childhood asthma and elevated IL-4 and IL-13.
1 Jun 2026· Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology· PUBMED
Publication
Dupilumab attenuate IL-4 and IL-13 synergistic effect on airway remodeling in asthma via blocking IL-4Rα/STAT6 axis.
30 May 2026· Scientific reports· PUBMED
Publication
First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity.
28 May 2026· Frontiers in immunology· PUBMED
Publication
Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review.
16 May 2026· Current allergy and asthma reports· PUBMED
Publication
Drug-induced sarcoidosis-like reaction following IL-4/IL-13 receptor blockade by dupilumab.
13 May 2026· European journal of pediatrics· PUBMED
Publication
Association Between IL-4 (rs2243250) and IL-13 (rs20541) Gene Polymorphisms and Total IgE Levels in Bronchial Asthma: A Study from Aswan Governorate, Egypt.
10 May 2026· Iranian journal of pathology· PUBMED
Publication
S100P mediates IL-13/ATF4-driven epithelial barrier dysfunction in eosinophilic asthma: a potential biomarker and therapeutic target.
24 Apr 2026· Journal of translational medicine· PUBMED
Publication
Vascular Immune Crosstalk in COVID-19: RAAS Biomarker Signature Linking Angiotensin II to Respiratory Compromise and Soluble ACE2 to IL-13 and FGF, Revealing Therapeutic Targets.
17 Apr 2026· International journal of molecular sciences· PUBMED
Publication
CM512, a potentially novel IgG1-based bispecific antibody dual-targeting TSLP and IL-13, for the suppression of type 2 inflammation.
10 Apr 2026· Journal of translational medicine· PUBMED
Publication
Design of binder proteins specific to IL-13.
2 Apr 2026· International journal of biological macromolecules· PUBMED